

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention Model Performance Evaluation Program

CD4⁺ T-Cell Determinations

Report of Results for the Performance Evaluation Survey Conducted in April 2003



PUBLIC HEALTH PRACTICE PROGRAM OFFICE DIVISION OF LABORATORY SYSTEMS ATLANTA, GEORGIA

Use of trade names is for identification only and does not constitute endorsement by the Department of Health and Human Services.

Analysis of the Testing Results Submitted by Laboratories Participating in the Centers for Disease Control and Prevention (CDC) Model Performance Evaluation Program (MPEP) for CD4⁺ T-Cell Determinations Conducted in April 2003

The production of this report was coordinated in CDC by:

Public Health Practice Program Office	Suzanne M. Smith, M.D., M.P.H., M.P.A.
v	Acting Director
Division of Laboratory Systems	Robert Martin, Dr.P.H., Director
Laboratory Practice Évaluation and Genomics Branch	
This report was developed and prepared by:	
Model Performance Evaluation Program (MPEP)	G. David Cross, M.S., Co-Manager

Questions about this report should be addressed to the Model Performance Evaluation Program by calling (770) 488-8091.

Table of Contents

Introduction	5
Significant Findings	5
Materials and Methods	5-6
Summary of Results	6-18
Discussion	

Tables

Table 1.	Donor Identification for April 2003 Shipment Specimens4
Table 2.	Total Percentage of Participant Laboratory Results Within or Outside the Established 95% Confidence Limits7
Table 3.	Laboratories Reporting Use of Single-Platform Methods for Absolute Cell Counts
Table 4.	Participant Laboratory Aggregate Results
Table 5.	Inclusive Range of Absolute T-cell Counts Reported, Single-Platform versus Multi-Platform Derived

Figures

Figure 1.	Types of Participant Laboratories	8
Figure 2.	Specimen Preparation Methods Used	9
Figure 3.	Methods of Specimen Fixation	10
Figure 4.	Types of Flow Cytometers Used	11
Figure 5.	Types of Hematology Instruments Used	12

Centers for Disease Control and Prevention Model Performance Evaluation Program for CD4⁺ T-Cell Determinations

Panel Letter	Participant Laboratory Vial Label	CDC Donor Number	Donor Information (HIV-1* status)
А	A1, A4 A2	02 03	HIV-1 Antibody-Positive HIV-1 Antibody-Negative
	A3	01	HIV-1 Antibody-Negative
	A5	05	HIV-1 Antibody-Positive
В	B1	01	HIV-1 Antibody-Negative
	B2	03	HIV-1 Antibody-Negative
	B3	05	HIV-1 Antibody-Positive
	B4, B5	04	HIV-1 Antibody-Positive
С	C1, C5	07	HIV-1 Antibody-Positive
	C2	08	HIV-1 Antibody-Negative
	C3	10	HIV-1 Antibody-Positive
	C4	09	HIV-1 Antibody-Negative
D	D1	08	HIV-1 Antibody-Negative
	D2, D4 D3	06 09	HIV-1 Antibody-Positive HIV-1 Antibody-Negative
	D3 D5	10	HIV-1 Antibody-Negative
	05	10	The TAILbouy POSILIVE

Table 1. Donor Identification for April 2003 Shipment Specimens

*Human immunodeficiency virus type 1

Analysis of the April 2003 Performance Evaluation Testing Results for CD4⁺ T-Cell Determinations Program Reported to the Centers for Disease Control and Prevention by Participating Laboratories

Introduction

This report analyzes testing results reported by laboratories participating in the Centers for Disease Control and Prevention (CDC) Model Performance Evaluation Program (MPEP) for after they tested the CD4⁺ T-cell determination (CD4⁺T-cell) performance evaluation specimens sent on April 8 and April 15, 2003. Of the 280 laboratories receiving specimen panels, 256 (91.4%) reported testing results. Of the 24 nonreporting laboratories, two returned results too late to be included in this data analysis and 22 provided no explanation.

Significant Findings

- The range of results reported for absolute CD4⁺ and CD8⁺ T-cell counts differed depending on the method used to obtain the result, i.e., single-platform or multiplatform. The ranges of multi-platform absolute CD4⁺ and CD8⁺ T-cell counts were significantly wider due to the large ranges of hematology instrument-derived absolute lymphocyte count results.
- The percentage of laboratories using single-platform methods, rather than multiplatform methods, to derive absolute CD4⁺ and CD8⁺ T-cell counts generally increased over the past five years, and has stabilized at around 30% for the past three survey periods (April 2002, September 2002, April 2003).
- According to the CDC guidelines for CD4⁺ T-cell testing (*MMWR*: 1997; 46, RR-2), specimens should be processed for hematologic testing and immunophenotyping within 30 hours after collection. In spite of receiving preshipment letters outlining when to expect receipt of the MPEP CD4⁺ PE specimens, 34 (13.3%) of the 256 participant laboratories reported they did not process the specimens on the day they were received.
- Only 17 Health Department laboratories participated in the April 2003 shipment. Most of the Nation's capability for performing CD4⁺ T-cell determinations appears to reside with hospital and independent laboratories. Presumably, most State and local Health Departments rely on hospital and independent laboratories to monitor CD4 T-cell levels in HIV-infected individuals receiving Government supported anti-retroviral therapy.

Materials and Methods

Each laboratory received a total of five whole blood specimens collected in K₃EDTA, three HIV-1 antibody-positive and two HIV-1 antibody-negative specimens. One of the HIV-1 antibody-positive whole blood specimens was sent to the participant laboratories in duplicate. Not all laboratories received the same panel of specimens. Table 1, page 4, contains the specimen numbers and donor information for each performance evaluation specimen.

Laboratories were notified a month in advance of the date they would be receiving specimens. An air-bill tracking number was included in these preshipment letters, enabling the laboratories to locate the specimens in the event the shipment was not received by noon on the scheduled date of their receipt. These notifications also allowed the laboratories to minimize withininstitution delivery delays. Participant laboratories were instructed to process and test the MPEP CD4⁺ T-cell specimens as they would patient specimens routinely received by their laboratory.

The result reporting booklet used for the April 2003 specimen shipment was designed to be consistent with the CDC guidelines for CD4⁺ T-cell testing (<u>MMWR</u>, vol. 46, no. RR-2, January 10, 1997). Laboratories were encouraged to use these guidelines in performing CD4⁺ T-cell determinations on patient specimens. According to these guidelines, specimens should be processed for hematologic testing and flow cytometric immunophenotyping within 30 hours of collection.

Methods used to derive the cell marker-specific absolute cell count were classified as either multi-platform or single-platform. Multi-platform methods are those which use the results from the flow cytometer (cell marker percentages) combined with the results from a hematology analyzer (white blood cell count, percent lymphocytes, and absolute lymphocyte count) to calculate the specific absolute cell count. Single-platform methods are those whereby the absolute cell count is derived using a single instrument (e.g., FACSCount, TruCount, or Flow-Count).

All cell marker percentage results reported by the laboratories were grouped according to the cell marker of interest, regardless of the flow cytometer or monoclonal antibody combination used to derive the specific result, e.g., CD4⁺ results were grouped from laboratories using CD3/CD4, CD3/CD4/CD8, CD45/CD3/CD4, and CD45/CD3/CD4/CD8. Similarly, regardless of the method used to obtain the absolute cell count (single-platform or multi-platform), all results for CD4⁺ and CD8⁺ absolute cell counts were grouped. These results were used to calculate 95% confidence limits for each donor and cell marker using the SAS procedure PROC GLM. Before calculation, data were analyzed for possible outliers. Only 235 (2.3%) of 10,357 results were considered to be outliers. These outlier results were removed before the 95% confidence limits shown in Table 3 were calculated. However, no data from any laboratory were removed from the aggregate results table comparing values obtained by the laboratories against the 95% confidence limits.

Because of insufficient data, 95% confidence limits could not be calculated for CD3⁻/CD16⁺. Table 3 shows the entire range of laboratory results (maximum and minimum) reported for this cell marker.

Summary of Results

In general, most laboratories performed well on the donor specimens in the April 2003 shipment. The percentages of participating laboratory results within the 95% confidence limits established for the cell marker percentage results, the marker specific absolute cell counts, white blood cell count, lymphocyte percentage, and absolute lymphocyte count are shown in Table 2.

Table 2.Total percentage of participant laboratory results within or outside the
established 95% confidence limits

	Cell Marke	r Percentage	Absolute Cell Counts		He	ematology Resu	ults
Cell Marker	Within 95% Confidence Limits	Outside 95% Confidence Limits	Within 95% Confidence Limits	Outside 95% Confidence Limits		Within 95% Confidence Limits	Outside 95% Confidence Limits
CD3⁺	93.6%	6.4%			White Blood Cell Count	93.6%	6.4%
CD4 ⁺	94.6%	5.4%	92.8%	7.2%	Lymphocyte Percentage	92.6%	7.4%
CD8⁺	95.0%	5.0%	92.2%	7.8%	Absolute Lymphocyte Count	90.6%	9.4%
CD14⁺	97.4%	2.6%					
CD19⁺	94.1%	5.9%					
CD45⁺	95.2%	4.8%					
CD56⁺	92.8%	7.2%					
CD(56+16) ⁺	93.4%	6.6%					

The types of laboratories participating in the April 2003 $CD4^+$ T-cell determinations shipment are shown in Figure 1.





Figure 1. Primary classification of laboratories participating in the April 2003 shipment.

Figure 2 shows the methods used by the laboratories to prepare specimens for CD4⁺ T-cell determinations. All of the laboratories performing multi-platform methods reported using a method of whole blood lysis to prepare specimens for CD4⁺ T-cell (including 2 methods described as "Other"). The frequency of preparation methods specific for single-platform methods is also reflected in Figure 2.

Figure 2. Methods used to prepare specimens for CD4⁺ T-cell determinations, reported by participant laboratories to CDC for the April 2003 shipment.



"Other" multi-platform methods were described as Coulter Prep Plus 2 and Cal-Lyse (CalTag). "Other" single-platform methods were described as Coulter HMX.

Figure 3 shows the methods used by the laboratories to fix their CD4⁺ T-cell specimens before flow cytometric analysis. Of laboratories reporting testing results, 33 (12.4%) of 267, specifically stated that they did not fix their CD4⁺ T-cell specimens before analyzing them, even though the panel sent to the laboratories contained known HIV antibody-positive specimens.

Figure 3. Methods used to fix specimens for CD4⁺ T-cell determinations, reported by participant laboratories to CDC for the April 2003 shipment.





Figure 4. Types of flow cytometers used for CD4⁺ T-cell determinations, reported by participant laboratories to CDC for the April 2003 shipment.



^{*} Not all laboratories reported the type of flow cytometer used

Among the 256 laboratories reporting results, 214 reported absolute cell counts. Of these, 150 (70.1%) of 214 used only a multi-platform method to derive marker-specific absolute cell counts. Sixty-three (29.5%) of 214 laboratories, used only a single-platform method. One laboratory reported results using both single- and multi-platform methods. Table 3 shows the number and percentage of laboratories reporting the use of single-platform methods generally increased during the past six years. However, the use of single-platform methods appears to have stabilized to around 30% during the past 12 months.

Table 3.	Laboratories	reporting use	e of single-platfor	m methods for	absolute cell counts
----------	--------------	---------------	---------------------	---------------	----------------------

	Sept.	March	Sept./Oct.	April	Oct.	April	Oct.	April	Oct.	April	Oct.	April
Shipments	1997	1998	1998	1999	1999	2000	2000	2001	2001	2002	2002	2003
Total # of												
Labs	162	188	188	208	205	198	206	205	210	215	219	214
Reporting												
# of Labs												
using	30	36	35	42	42	51	51	57	57	67	67	64
Single-	30	30		42	42	51	51	57	57	07	07	04
Platform												
% of Labs												
using	18.5	19.1	18.6	20.2	20.5	25.8	24.7	27.8	27.1	31.2	30.6	29.9
Single-	10.0	19.1	10.0	20.2	20.5	20.0	24.7	21.0	21.1	31.2	30.0	29.9
Platform												

CDC Model Performance Evaluation Program CD4⁺ T-cell Determinations

Of the 256 participant laboratories, 165 (64.5%) identified the manufacturer of the hematology instrument in use in their laboratory. These manufacturers are shown in Figure 5.




Figure 5. Hematology instruments, by manufacturer, used for CD4⁺ T-cell determinations, reported by participant laboratories to CDC for the April 2003 shipment.

Cell Marker Statistical Calculations and Results

Table 4 contains the frequency of participant laboratory lymphocyte immunophenotyping percentage results by donor and cell marker, within, above, or below the 95% confidence limits established using results from all laboratories, regardless of the monoclonal antibody combination or manufacturer of flow cytometry instrument used to obtain these percentage results. The table also contains the frequency of participant laboratory hematology results (white blood cell count, percentage of lymphocytes and absolute lymphocyte count) and absolute cell count results for CD4⁺ and CD8⁺, within, above, or below the statistically established 95% confidence limits.

Donor Number	1 - Donor	Statu	s: HIV	-antibody Ne	gative
	Percent	tage		Absolute	
Cell	Resu	ts		Counts	
Marker	Range		No.	Range	No.
	>	100	0		
CD45	95 -	100	19		
	<	95	1		
	>	1	1		
CD14	0 -	1	19		
	<	0	0		_
	>	69	3	> 1,94	
CD4	58 -	69	109	489 - 1,94	
	<	58	4	< 489	
	>	26	1	> 745	
CD8	21 -	26	109	167 - 745	
	<	21	6 1	< 167	′ 1
0040	>	7			
CD19	3 -	7 3	93 0		
	<		-		
CD56	>	6	2		
CD56	1 -	6 1	30 0		
	>	8	0		
CD56+16	3 -	о 8	56		
CD30+10		3	5		
	>	94	1		
CD3 Average	82 -	94	103		
SD0 Average	<	82	3		
	3 -				
CD16	J -	5	3	1	

Hematology Results

Hematology Parameter	Range	No.
WBC	> 9,921 5,282 - 9,921 < 5,282	1 73 0
% Lymphs	> 40 17 - 40 < 17	4 67 1
Absolute Lymphs	> 3,442 837 - 3,442 < 837	5 65 2

Legend:

95% Confidence limits highlighted"No." represents number of laboratories reporting in these ranges.No confidence limits established for

CD16 - maximum and minimum values reported

Donor Number 2 - Donor Status: HIV-antibody Positive

Cell	Percentage Results		Absolute Counts	
Marker	Range	No.	Range	No.
CD45	> 100 93 - 100 < 93	0 22 2		
CD14	> 2 0 - 2 < 0	0 24 0		
CD4	> 51 42 - 51 < 42	1 110 5	> 1,104 603 - 1,104 < 603	10 108 2
CD8	> 25 20 - 25 < 20	2 111 3	> 551 282 - 551 < 282	10 109 1
CD19	> 20 13 - 20 < 13	5 87 4		
CD56	> 10 6 - 10 < 6	3 33 0		
CD56+16	> 19 6 - 19 < 6	0 48 4		
CD3 Average	> 75 64 - 75 < 64	6 99 1		
CD16	10 - 15	4	12	

Hematology Parameter	Range	No.
WBC	> 6,975 5,773 - 6,975 < 5,773	1 73 2
% Lymphs	> 41 20 - 41 < 20	8 65 1
Absolute Lymphs	> 2,618 1,261 - 2,618 < 1,261	5 66 3

	Percentage		Absolute	
Cell	Results		Counts	
Marker	Range	No.	Range	No.
IVIAINEI	> 100	0	Range	INO.
CD45	96 - 100	18		
0040	< 96	2		
	> 1	1		
CD14	0 - 1	19		
0014	v - 1 	0		
	> 52	4	> 1,124	4
CD4	45 - 52	106	769 - 1,124	
-	< 45	6	< 769	3
	> 28	3	> 574	3
CD8	22 - 28	110	390 - 574	101
	< 22	3	< 390	4
	> 17	2		
CD19	12 - 17	84		
	< 12	8		
	> 9	2		
CD56	5 - 9 < 5	30		
	-	0		
	> 11	2		
CD56+16	6 - 11 < 6	57 2		
	< 6 > 79	5		
CD3 Average	73 - 79	98		
CDS Average	< 73	90 4		
CD16	7 - 8	3		

Donor Number 3 - Donor Status: HIV-antibody Negative

Hematology Results

Hematology Parameter	Range	No.
WBC	> 7,036 6,059 - 7,036 < 6,059	2 68 4
% Lymphs	> 35 26 - 35 < 26	4 69 0
Absolute Lymphs	> 2,364 1,634 - 2,364 < 1,634	3 67 3

Legend:

95% Confidence limits highlighted"No." represents number of laboratories reporting in these ranges.No confidence limits established for

CD16 - maximum and minimum values reported

Donor Number 4 - Donor Status: HIV-antibody Positive

	Percentage		Absolute	
Cell	Results		Counts	
Marker	Range	No.	Range	No.
CD45	> 100 97 - 100 < 97	0 16 0		
CD14	> 0 0 - 0 < 0	2 14 0		
CD4	> 33 27 - 33 < 27	4 110 2	> 713 531 - 713 < 531	5 93 2
CD8	> 55 49 - 55 < 49	6 110 0	> 1,208 927 - 1,208 < 927	5 89 2
CD19	> 11 7 - 11 < 7	1 88 3		
CD56	> 4 2 - 4 < 2	1 27 0		
CD56+16	> 6 2 - 6 < 2	2 68 0		
CD3 Average	> 89 82 - 89 < 82	3 101 4		
CD16	3 - 3	2		

Hematology Parameter	Range	No.
WBC	> 4,567 4,024 - 4,567 < 4,024	5 66 1
% Lymphs	> 51 45 - 51 < 45	3 69 0
Absolute Lymphs	> 2,340 1,795 - 2,340 < 1,795	2 66 4

0 "	Percentage		Absolute	
Cell	Results		Counts	
Marker	Range	No.	Range	No.
00.45	> 100	0		
CD45	93 - 100	20		
	< 93	0		
0044	> 3	0		
CD14	0 - 3	20		
	< 0 > 10	0	> 171	7
CD4	6 - 10	109	> 1/1 76 - 171	100
CD4	< 6	108	< 76 < 76	100
	> 68	2	> 1,238	3 6
CD8	56 - 68	107	617 - 1,238	
000	< 56	5	< 617	1
	> 5	5		
CD19	1 - 5	88		
	< 1	0		
	> 19	1		
CD56	11 - 19	30		
	< 11	1		
	> 28	1		
CD56+16	13 - 28	56		
	< 13	3		
	> 82	2		
CD3 Average	68 - 82	100		
	< 68	4		
CD16	14 - 22	3		

Donor Number 5 - Donor Status: HIV-antibody Positive

Hematology Results

Hematology Parameter	Range	No.
WBC	> 5,628 4,759 - 5,628 < 4,759	1 68 5
% Lymphs	> 37 23 - 37 < 23	4 68 1
Absolute Lymphs	> 1,979 1,103 - 1,979 < 1,103	3 66 4

Legend:

95% Confidence limits highlighted"No." represents number of laboratories reporting in these ranges.No confidence limits established for

CD16 - maximum and minimum values reported

Donor Number 6 - Donor Status: HIV-antibody Positive

		-	antibody i osi	
	Percentage		Absolute	
Cell	Results		Counts	
Marker	Range	No.	Range	No.
	> 100	0		
CD45	96 - 100	34		
	< 96	0		
	> 1	0		
CD14	0 - 1	34		
	< 0	0		
	> 54	4	> 1,958	6
CD4	47 - 54	122	1,366 - 1,958	112
	< 47	0	< 1,366	2
	> 38	4	> 1,358	6
CD8	33 - 38	120	962 - 1,358	108
	< 33	0	< 962	6
	> 11	1		
CD19	6 - 11	90		
	< 6	5		
0.050	> 2	2		
CD56	0 - 2	36 0		
	-	-		
	> 3	2		
CD56+16	0 - 3 < 0	52 0		
	-	-		
	> 93	6		
CD3 Average	87 - 93 < 87	93		
	< 87			
CD16	0 - 1	4	15	

Hematology Parameter			
WBC	> 6,578 5,624 - 6,578 < 5,624	3 76 3	
% Lymphs	> 59 51 - 59 < 51	2 77 3	
Absolute Lymphs	> 3,933 2,828 - 3,933 < 2,828	4 75 3	

Donor Number	7 - Donor	Statu	s: HIV	-antibody Pos	itive
	Percentage		Absolute		
Cell	Resul	ts		Counts	
Marker	Range		No.	Range	No.
	>	100	0		
CD45	94 -	100	31		
	<	94	3		
	>	1	0		
CD14	0 -	1	33		
	<	0	0		
	>	28	4	> 1,137	1
CD4	- 22	28	114	536 - 1,137	83
	<	22	2	< 536	6
	>	58	9	> 2,319	
CD8	51 -	58	110	1,325 - 2,319	
	<	51	1	< 1,325	6
	>	16	2		
CD19	7 -	16	99		
	<	7	3		
	>	3	2		
CD56	1 -	3	32		
	<	1	2		
0050 40	>	8	2		
CD56+16	2 -	8	58		
	<	2	2		
	>	85	4		
CD3 Average	78 -	85	91		
	<	78	1		
CD16	5 -	7	4		

Hematology Results

Hematology Parameter	Range	No.
WBC	> 9,210 5,337 - 9,210 < 5,337	0 76 8
% Lymphs	> 52 41 - 52 < 41	2 80 2
Absolute Lymphs	> 4,245 2,487 - 4,245 < 2,487	0 75 7

Legend:

95% Confidence limits highlighted"No." represents number of laboratories reporting in these ranges.No confidence limits established for

CD16 - maximum and minimum values reported

Donor Number 8 - Donor Status: HIV-antibody Negative

		••••••	antibody Neg	
	Percentage		Absolute	
Cell	Results		Counts	
Marker	Range	No.	Range	No.
	> 100	0		
CD45	93 - 100	32		
	< 93	2		
	> 2	0		
CD14	0 - 2	34		
	< 0	0		
	> 57	3	> 1,499	8
CD4	50 - 57	116	745 - 1,499	• • • • • • • • • • • • • • • • • • • •
	< 50	4	< 745	0
0.5.0	> 20	3	> 533	7
CD8	16 - 20	119	246 - 533	96
	< 16 > 20	0	< 246	2
0040				
CD19	11 - 20	95 3		
		0		
CD56	> 10 4 - 10	35		
CD30	4 - 10 < 4	2		
	> 13	1		
CD56+16	7 - 13	55		
0000110	< 7	2		
	> 77	4		
CD3 Average	69 - 77	92		
	< 69	2		
CD16				
CD16	7 - 11	4	Ш	

Hematology Parameter	Range	No.
WBC	> 7,38 6,088 - 7,38 < 6,08	9 78
% Lymphs	> 44 20 - 44 < 20	8 75 0
Absolute Lymphs	> 3,25 1,210 - 3,25 < 1,21	6 73

	9 - Donor Statu				
	Percentage		Absolute		
Cell	Results		Counts		
Marker	Range No.		Range	No.	
	> 100	0			
CD45	95 - 100	32			
	< 95	2			
	> 2	2			
CD14	0 - 2	32			
	< 0	0			
	> 53	5	> 1,966	8	
CD4	47 - 53	116	1,151 - 1,966	97	
	< 47	2	< 1,151	0	
	> 27	2	> 962	8	
CD8	22 - 27	119	554 - 962	97	
	< 22	1	< 554	0	
	> 23	1			
CD19	15 - 23	93			
	< 15	6			
	> 4	3			
CD56	0 - 4	34			
	< 0	0			
	> 5	4			
CD56+16	2 - 5	53			
	< 2	1			
	> 80	6			
CD3 Average	73 - 80	91			
go	< 73	1			
CD16	2 - 3	4	1		

Donor Number 9 - Donor Status: HIV-antibody Negative

Hematology Results

Hematology Parameter	Range	No.
WBC	> 8,145 6,992 - 8,145 < 6,992	2 79 2
% Lymphs	> 52 31 - 52 < 31	7 76 0
Absolute Lymphs	> 4,060 2,349 - 4,060 < 2,349	6 74 2

Legend:

95% Confidence limits highlighted
"No." represents number of laboratories reporting in these ranges.
No confidence limits established for CD16 - maximum and minimum values

reported

Donor Number 10 - Donor Status: HIV-antibody Positive

	Percentage		Absolute		
Cell	Results		Counts		
Marker	Range	No.	Range	No.	
	> 100	0			
CD45	91 - 100	32			
	< 91	1			
	> 1	1			
CD14	0 - 1	32			
	< 0	0	0.40		
05.4	> 9	6	> 242	4	
CD4	6 - 9	116	39 - 242	101	
	< 6	1	< 39	0	
0.00	> 50	9	> 1,049		
CD8	38 - 50 < 38	113 0	567 - 1,049 < 567	98 0	
	> 19	1	< 307	0	
CD19	9 - 19	95			
CD19	< 9	4			
	> 33	2			
CD56	10 - 33	33			
	< 10	2			
	> 40	1			
CD56+16	28 - 40	52			
	< 28	5			
	> 59	8			
CD3 Average	45 - 59	90			
	< 45	0			
CD16	28 - 34	4			

Hematology Parameter	Range	No.
WBC	> 5,372 4,072 - 5,372 < 4,072	1 78 4
% Lymphs	> 48 30 - 48 < 30	7 75 1
Absolute Lymphs	> 2,353 1,381 - 2,353 < 1,381	6 74 2

As can be seen in Table 5, the range of results reported for absolute CD4⁺ and CD8⁺ T-cell counts was different depending on the method used to obtain the result, i.e., single-platform vs. multi-platform. Note: These are inclusive ranges (lowest value to highest value) and are <u>not</u> 95% confidence limits as presented in the results in the previous tables.

		CD4 ⁺ T-cell Count		CD8 ⁺ T-cell Count		Absolute Lymphocyte Count
Vial	Donor	Single-	Multi-	Single-	Multi-	(Hematology
Label	Identification	Platform	Platform	Platform	Platform	Instrument)
A3, B1	1	841 - 1124	64 - 3244	305 - 428	20 - 1097	156 – 4770
A1, A4	2	662 - 1771	42 - 1690	290 - 947	24 - 810	1144 – 3520
A2, B2	3	737 - 1322	42 - 1287	342 - 719	22 - 630	185 – 2600
B4, B5	4	523 - 762	487 - 985	922 - 1255	937 - 1684	196 – 3178
A5, B3	5	76 - 145	6 – 232	634 - 988	61 – 1738	140 – 2650
D2, D4	6	1304 - 1844	274 – 2788	874 – 1285	192 – 1989	326 - 5510
C1, C5	7	471 – 955	216 – 1287	1235 – 2086	1132 – 2334	2000 - 4244
C2, D1	8	869 - 1107	746 - 3047	312 – 409	234 - 1045	199 – 5500
C4, D3	9	1249 - 1639	1159 - 3605	599 - 843	566 - 1730	320 – 5310
C3, D5	10	94 - 163	97 - 1520	631 - 840	574 - 2360	182 - 5076

Table 5.Inclusive* Range of Absolute T-cell Counts Reported, Single-Platform vs.Multi-Platform Derived

* Inclusive ranges – smallest to largest value, <u>not</u> 95% confidence limits

The multi-platform ranges were larger than the corresponding single-platform ranges for both CD4⁺ and CD8⁺ absolute T-cell counts (on average, more than 3.5 times larger). The ranges of multi-platform results were affected by the magnitude of the ranges of the absolute lymphocyte count results (last column), which were often quite large (e.g., Donors 1, 6, 9, and 10). For some, the magnitude of the ranges may be due to simple reporting errors on the part of the laboratories. For example, one laboratory for all five specimens tested reported a lymphocyte count result that was in error by nearly a factor of 10 (e.g., the laboratory reported a WBC of 6190 and a lymphocyte percent of 25, which should have yielded a lymphocyte count of 1548; however, the laboratory reported a lymphocyte count of 156). Eleven laboratories reported lymphocyte counts that differed by more than 5% from the true calculated lymphocyte count (WBC X Lymphocyte percent) on at least one specimen. Of the 11, three laboratories inaccurately calculated lymphocyte counts (greater than 5% difference between true and reported) on all 5 specimens tested. The MPEP for CD4⁺ T-cell determinations focuses on the total testing process, including errors resulting from incorrect calculations.

Discussion

Specimen panel receipt was delayed one day for seven laboratories due to problems related to the overnight carrier. Nine laboratories reported a one-day delay in receiving their specimens due to delivery problems within their institution. Additionally, 34 (13.3%) of 256 laboratories reported they did not process the MPEP CD4⁺ T-cell specimens on the day they were received (32 laboratories, one-day delay; two laboratories, two-day delay). These delays may have affected the testing results from these laboratories.

Differences in laboratory performance of cell marker analysis may be related to:

- the use of the CDC CD4⁺ T-cell testing guidelines
- the use of multi-platform versus single-platform procedures
- the use of different flow cytometer, hematology instrument, and reagent manufacturer combinations
- factors associated with specimen preparation (including specimen fixation before analysis and delay in preparing specimens for analysis), and
- reporting errors on the part of the laboratories.

Those laboratories performing CD4⁺ T-cell determinations using a single-platform method should follow the recently published CDC *Guidelines for Performing Single-Platform Absolute CD4*+ *T-Cell Determinations with CD45 Gating for Persons Infected with Human Immunodeficiency Virus* [MMWR 2003; 52(RR-2):1-13].